Polyrizon Announces Closing of $4.2 Million Initial Public Offering
Polyrizon Ltd. (the "Company" or "PLRZ"), a development stage biotech company specializing in the development of innovative medical device hydrogels, today announced the closing of its underwritten ...
Polyrizon Announces Pricing of $4.2 Million Initial Public Offering and Listing on the Nasdaq Capital Market Under New Ticker “PLRZ”
PLRZ also announced that, in connection with the offering, its ordinary shares been approved for listing and are expected to begin trading on the Nasdaq Capital Market under the symbol "PLRZ” on ...
Aegis Capital Corp. Acted as Sole Bookrunner on a $4.2 Million (IPO) Initial Public Offering for Polyrizon Ltd. (NASDAQ: PLRZ)
NEW YORK, NY / ACCESSWIRE / October 30, 2024 / Aegis Capital Corp. acted as Sole Bookrunner on a $4.2 Million (IPO) Initial ...
Medscape12d
Strategies for Improving Mucosal Drug Delivery
The mucosal route plays an important role in nanoscale delivery. The nanoscale systems have to penetrate or diffuse through the mucosal membrane to reach the epithelium as depicted in Figure 3A ...
Aegis Capital Corp. Acted as Sole Bookrunner on a $4.2 Million Initial Public Offering for Polyrizon Ltd.
NEW YORK, NY / ACCESSWIRE / October 30, 2024 / Aegis Capital Corp. acted as Sole Bookrunner on a $4.2 Million (IPO) Initial Public Offering for Polyrizon Ltd. (NASDAQ:PLRZ).About Polyrizon Ltd.Polyriz ...
Polyrizon Ltd.: Polyrizon Announces Closing of $4.2 Million Initial Public Offering
Polyrizon Ltd. (the "Company" or "PLRZ"), a development stage biotech company specializing in the development of innovative medical device hydrogels ...